摘要
目的:许多基因治疗方案可以诱导产生抗肿瘤免疫反应,但是ex vivo的操作方式限制了其应用.本研究采用瘤体内直接注射MHC Ⅱ类基因的方法来诱导抗肿瘤免疫反应.方法:针对具有弱免疫原性的小鼠肥大细胞瘤P815和非免疫原性的小鼠黑色素瘤B16,在瘤体的原位注射MHC Ⅱ类基因,观察肿瘤的生长情况.结果:直接注射MHC Ⅱ类基因,使P815肿瘤的致瘤性明显下降,并且对第二次接种P815细胞具有抵抗能力;虽然对B16而言,仅注射MHC Ⅱ类基因无治疗效果,但与B7基因共同注射,却能够显著地抑制B16肿瘤的生长.结论:瘤体内直接注射MHC Ⅱ类基因可以用来进行肿瘤治疗.
Many gene therapy protocols can induce antitumor immunity, however, the ex vivo approach restricts their uses. This sutydy intended to induce antitumor immunity by direct transfer of MHC class Ⅱ gene in vivo. Methods: MHC class Ⅱ gene cDNA was introduced directly into two tumors: P815, (a murine weak immunogenic mas-tocytoma) and B16 (a murine nonirnmunogenic melanoma) to observe the survival rate of the mice. Results: Tumori-genicity of P815 was reduced when MHC class Ⅱ gene was introduced directly into tumors in vivo. Further more, most vaccinated mice could survive after second challenge of P815. Co-injection of MHC class Ⅱ and B7 genes in the B16 also resulted in the tumor grow slowly, while the injection of MHC class Ⅱ gene was not enough to induce effective antitumor responses. Conclusion: The results showed the potential applications of direct transfer of MHC class Ⅱ gene in the treatment of tumor.
出处
《中国肿瘤生物治疗杂志》
CAS
CSCD
1999年第2期117-120,共4页
Chinese Journal of Cancer Biotherapy
